dehydroepiandrosterone has been researched along with Cancer of Cervix in 8 studies
Dehydroepiandrosterone: A major C19 steroid produced by the ADRENAL CORTEX. It is also produced in small quantities in the TESTIS and the OVARY. Dehydroepiandrosterone (DHEA) can be converted to TESTOSTERONE; ANDROSTENEDIONE; ESTRADIOL; and ESTRONE. Most of DHEA is sulfated (DEHYDROEPIANDROSTERONE SULFATE) before secretion.
dehydroepiandrosterone : An androstanoid that is androst-5-ene substituted by a beta-hydroxy group at position 3 and an oxo group at position 17. It is a naturally occurring steroid hormone produced by the adrenal glands.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Patients with cervical cancer, in particular, have severely compromised QOL, providing a population well-suited for the evaluation of novel psychosocial interventions and the exploration of mechanisms by which modulation of the psychoneuroimmune axis might result in improved clinical outcomes." | 2.73 | Stress, immunity, and cervical cancer: biobehavioral outcomes of a randomized clinical trial [corrected]. ( Chantana, N; Chicz-DeMet, A; Dogan-Ates, A; du Pont, N; Laust, AK; Monk, BJ; Nelson, EL; Nishimoto, KP; Osann, K; Reina-Patton, A; Wenzel, LB, 2008) |
| "Dehydroepiandrosterone (DHEA) is an adrenal steroid that has both immune modulatory and tumor inhibitory activity." | 2.71 | Long-term administration of intravaginal dehydroepiandrosterone on regression of low-grade cervical dysplasia--a pilot study. ( Del Carmen, M; Duska, LR; Seiden, MV; Sivret, J; Suh-Burgmann, E, 2003) |
| "Our results indicated the anti-cervix cancer mechanism of G6PD deficiency may be involved with the decreased cancer cells migration and proliferation ability as a result of abnormal reorganization of cell cytoskeleton and abnormal biomechanical properties caused by the increased ROS." | 1.43 | Effects of G6PD activity inhibition on the viability, ROS generation and mechanical properties of cervical cancer cells. ( Chen, R; Chen, X; Fang, Z; Feng, Y; Guo, Y; Han, L; Jiang, C; Jiang, W; Li, H; Lin, X; Zhang, Z, 2016) |
| "Dehydroepiandrosterone (DHEA) has a protective role against epithelial-derived carcinomas; however, the mechanisms remain unknown." | 1.35 | Dehydroepiandrosterone inhibits the proliferation and induces the death of HPV-positive and HPV-negative cervical cancer cells through an androgen- and estrogen-receptor independent mechanism. ( Escobar, ML; Girón, RA; López-Marure, R; Montaño, LF, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (37.50) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (50.00) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fang, Z | 1 |
| Jiang, C | 1 |
| Feng, Y | 1 |
| Chen, R | 1 |
| Lin, X | 1 |
| Zhang, Z | 1 |
| Han, L | 1 |
| Chen, X | 1 |
| Li, H | 1 |
| Guo, Y | 1 |
| Jiang, W | 1 |
| Girón, RA | 1 |
| Montaño, LF | 1 |
| Escobar, ML | 1 |
| López-Marure, R | 1 |
| Suh-Burgmann, E | 1 |
| Sivret, J | 1 |
| Duska, LR | 1 |
| Del Carmen, M | 1 |
| Seiden, MV | 1 |
| Bradlow, HL | 1 |
| Sepkovic, DW | 1 |
| Nelson, EL | 1 |
| Wenzel, LB | 1 |
| Osann, K | 1 |
| Dogan-Ates, A | 1 |
| Chantana, N | 1 |
| Reina-Patton, A | 1 |
| Laust, AK | 1 |
| Nishimoto, KP | 1 |
| Chicz-DeMet, A | 1 |
| du Pont, N | 1 |
| Monk, BJ | 1 |
| Rao, AR | 1 |
| Mezinova, NN | 1 |
| Krivets, NA | 1 |
| Riessbeck, KH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Removing Surrogates' Uncertainty to Reduce Fear and Anxiety After Cardiac Events (RESURFACE): A Randomized Pilot Intervention Study[NCT06048068] | 100 participants (Anticipated) | Interventional | 2023-09-07 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for dehydroepiandrosterone and Cancer of Cervix
| Article | Year |
|---|---|
Steroids as procarcinogenic agents.
Topics: Androgens; Breast Neoplasms; Carcinogens; Cell Line, Tumor; Cytochrome P-450 CYP1A1; Cytochrome P-45 | 2004 |
2 trials available for dehydroepiandrosterone and Cancer of Cervix
| Article | Year |
|---|---|
Long-term administration of intravaginal dehydroepiandrosterone on regression of low-grade cervical dysplasia--a pilot study.
Topics: Administration, Intravaginal; Adult; Androstenedione; Antineoplastic Agents; Dehydroepiandrosterone; | 2003 |
Stress, immunity, and cervical cancer: biobehavioral outcomes of a randomized clinical trial [corrected].
Topics: Counseling; Dehydroepiandrosterone; Female; Humans; Hydrocortisone; Immunity; Interferon-gamma; Inte | 2008 |
5 other studies available for dehydroepiandrosterone and Cancer of Cervix
| Article | Year |
|---|---|
Effects of G6PD activity inhibition on the viability, ROS generation and mechanical properties of cervical cancer cells.
Topics: Actin Cytoskeleton; Apoptosis; Biomechanical Phenomena; Cell Movement; Cell Shape; Cell Survival; Cy | 2016 |
Dehydroepiandrosterone inhibits the proliferation and induces the death of HPV-positive and HPV-negative cervical cancer cells through an androgen- and estrogen-receptor independent mechanism.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Death; Cell Line, Tumor; Cell Proliferation; Dehy | 2009 |
Inhibitory action of dehydroepiandrosterone on methylcholanthrene-induced carcinogenesis in the uterine cervix of mouse.
Topics: Animals; Dehydroepiandrosterone; Diet; Female; Methylcholanthrene; Mice; Uterine Cervical Neoplasms | 1989 |
[The concentration of 17-neutral ketosteroids and dehydroepiandrosterone in the urine of patients with precancerous diseases and cancer of the uterine cervix].
Topics: 17-Ketosteroids; Adult; Dehydroepiandrosterone; Female; Humans; Middle Aged; Precancerous Conditions | 1969 |
[On a functional examination of the adrenal cortex for the purpose of radiotherapy].
Topics: 17-Ketosteroids; Adolescent; Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Adult; Bone Neopl | 1967 |